Lipidomics in non-alcoholic fatty liver disease

被引:0
|
作者
Sofia Kartsoli [1 ]
Christina E Kostara [2 ]
Vasilis Tsimihodimos [3 ]
Eleni T Bairaktari [2 ]
Dimitrios K Christodoulou [1 ]
机构
[1] Department of Gastroenterology, School of Health Sciences, Faculty of Medicine, University of Ioannina
[2] Laboratory of Clinical Chemistry, School of Health Sciences, Faculty of Medicine, University of Ioannina
[3] Department of Internal Medicine, School of Health Sciences, Faculty of Medicine, University of Ioannina
关键词
D O I
暂无
中图分类号
R575.5 [肝代谢障碍];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease(NAFLD), the most common chronic liver disorder in Western countries, comprises steatosis to nonalcoholic steatohepatitis(NASH), with the latter having the potential to progress to cirrhosis. The transition from isolated steatosis to NASH is still poorly understood, but lipidomics approach revealed that the hepatic lipidome is extensively altered in the setting of steatosis and steatohepatitis and these alterations correlate with disease progression. Recent data suggest that both quantity and quality of the accumulated lipids are involved in pathogenesis of NAFLD. Changes in glycerophospholipid, sphingolipid, and fatty acid composition have been described in both liver biopsies and plasma of patients with NAFLD, implicating that specific lipid species are involved in oxidative stress, inflammation, and cell death. In this article, we summarize the findings of main human lipidomics studies in NAFLD and delineate the currently available information on the pathogenetic role of each lipid class in lipotoxicity and disease progression.
引用
收藏
页码:436 / 450
页数:15
相关论文
共 50 条
  • [41] Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Stavropoulos, Konstantinos
    Imprialos, Konstantinos
    Pittaras, Andreas
    Faselis, Charles
    Narayan, Puneet
    Kokkinos, Peter
    CURRENT VASCULAR PHARMACOLOGY, 2018, 16 (03) : 239 - 245
  • [42] An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia
    Hsu, Ching-Sheng
    Kao, Jia-Horng
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (08) : 759 - 772
  • [43] Surgical Treatment of Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease
    Weiner, R. A.
    DIGESTIVE DISEASES, 2010, 28 (01) : 274 - 279
  • [44] The epidemiology of non-alcoholic fatty liver disease
    Bellentani, Stefano
    LIVER INTERNATIONAL, 2017, 37 : 81 - 84
  • [45] Non-alcoholic fatty liver disease in children
    Chaturvedi, Kanupriya
    Vohra, Pankaj
    INDIAN PEDIATRICS, 2012, 49 (09) : 757 - 758
  • [46] Pathology of non-alcoholic fatty liver disease
    Bedossa, Pierre
    LIVER INTERNATIONAL, 2017, 37 : 85 - 89
  • [47] Non-alcoholic fatty liver disease and diabetes
    Reyes-Garcia, Rebeca
    Rozas-Moreno, Pedro
    Julio Llamoza-Torres, Camilo
    Mezquita-Raya, Pedro
    MEDICINA CLINICA, 2017, 148 (01): : 33 - 38
  • [48] Hyperuricemia in non-alcoholic fatty liver disease
    Dogru, T.
    Genc, H.
    Tapan, S.
    Bagci, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (08) : 1042 - 1043
  • [49] Mitochondria in non-alcoholic fatty liver disease
    Prip-Buus, C.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2016, 46 : 53 - 53
  • [50] Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV
    Verna, Elizabeth C.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (03): : 211 - 223